Cargando…

In Silico Design of a Peptidomimetic Carrier for Levodopa

Ab initio molecular orbital calculations at the Hartree Fock level utilizing 6-31G basis set have been performed on small cyclic peptides and peptidomimetic compounds to explore their utility as carriers of levodopa (L-3,4-dihydroxyphenylalanine) to enhance its brain bioavailability. A cyclic peptid...

Descripción completa

Detalles Bibliográficos
Autores principales: Banerjee, A., Yadav, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Master Publishing Group 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3614811/
https://www.ncbi.nlm.nih.gov/pubmed/23675219
_version_ 1782264921460834304
author Banerjee, A.
Yadav, A.
author_facet Banerjee, A.
Yadav, A.
author_sort Banerjee, A.
collection PubMed
description Ab initio molecular orbital calculations at the Hartree Fock level utilizing 6-31G basis set have been performed on small cyclic peptides and peptidomimetic compounds to explore their utility as carriers of levodopa (L-3,4-dihydroxyphenylalanine) to enhance its brain bioavailability. A cyclic peptidomimetic compound with hydrophobic CH(2)NH backbone is suggested as possible carrier. This carrier is predicted to efficiently carry Levodopa held by non covalent interactions encompassed in its cyclic backbone without chances of expulsion before delivery inside brain. Carrier is expected to undergo passive diffusion alongwith the drug held inside. Once inside the brain, drug may be delivered enzymatically or non enzymatically.
format Online
Article
Text
id pubmed-3614811
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Master Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-36148112013-05-01 In Silico Design of a Peptidomimetic Carrier for Levodopa Banerjee, A. Yadav, A. Int J Biomed Sci Article Ab initio molecular orbital calculations at the Hartree Fock level utilizing 6-31G basis set have been performed on small cyclic peptides and peptidomimetic compounds to explore their utility as carriers of levodopa (L-3,4-dihydroxyphenylalanine) to enhance its brain bioavailability. A cyclic peptidomimetic compound with hydrophobic CH(2)NH backbone is suggested as possible carrier. This carrier is predicted to efficiently carry Levodopa held by non covalent interactions encompassed in its cyclic backbone without chances of expulsion before delivery inside brain. Carrier is expected to undergo passive diffusion alongwith the drug held inside. Once inside the brain, drug may be delivered enzymatically or non enzymatically. Master Publishing Group 2011-03 /pmc/articles/PMC3614811/ /pubmed/23675219 Text en © A. Banerjee et al. Licensee Master Publishing Group http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.5/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Article
Banerjee, A.
Yadav, A.
In Silico Design of a Peptidomimetic Carrier for Levodopa
title In Silico Design of a Peptidomimetic Carrier for Levodopa
title_full In Silico Design of a Peptidomimetic Carrier for Levodopa
title_fullStr In Silico Design of a Peptidomimetic Carrier for Levodopa
title_full_unstemmed In Silico Design of a Peptidomimetic Carrier for Levodopa
title_short In Silico Design of a Peptidomimetic Carrier for Levodopa
title_sort in silico design of a peptidomimetic carrier for levodopa
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3614811/
https://www.ncbi.nlm.nih.gov/pubmed/23675219
work_keys_str_mv AT banerjeea insilicodesignofapeptidomimeticcarrierforlevodopa
AT yadava insilicodesignofapeptidomimeticcarrierforlevodopa